Ardelyx Launches Irritable Bowel Syndrome Treatment Ibsrela
April 14, 2022
Pfizer Recalls Five Lots of Accupril
April 22, 2022
Ardelyx Launches Irritable Bowel Syndrome Treatment Ibsrela
April 14, 2022
Pfizer Recalls Five Lots of Accupril
April 22, 2022

April 21, 2022 – Zerbaxa® (ceftolozane/tazobactam) has received an expanded indication to treat complicated intra-abdominal infections and complicated urinary tract infections, including pyelonephritis, in patients of all ages. It was previously approved for this use only in adults.

  • First FDA approved in 2014, Zerbaxa is also indicated to treat adults who have hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
  • Recommended dosing and the duration of treatment are based on factors such as the patient’s age, weight, renal health, and diagnosis.